| scholarly article | Q13442814 |
| P50 | author | Linda P. Fried | Q6551880 |
| Karen Bandeen-Roche | Q42055725 | ||
| Marilyn S. Albert | Q56861968 | ||
| Michelle M Mielke | Q60909929 | ||
| Constantine G. Lyketsos | Q91213781 | ||
| Peter V. Rabins | Q112424479 | ||
| P2093 | author name string | Norman J Haughey | |
| Michelle C Carlson | |||
| Sevil Yasar | |||
| Vijay Varma | |||
| Greg Harris | |||
| Eric B Schneider | |||
| Jin Xia | |||
| Veera Vankata Ratnam Bandaru | |||
| P2860 | cites work | Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics | Q21560953 |
| Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes | Q24532064 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Deregulation of sphingolipid metabolism in Alzheimer's disease | Q33693061 | ||
| Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis | Q34007818 | ||
| Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss | Q34106300 | ||
| Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein | Q34649008 | ||
| Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? | Q35086073 | ||
| Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease | Q36004699 | ||
| Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway | Q36321788 | ||
| Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease | Q36604677 | ||
| Frequency and course of mild cognitive impairment in a multiethnic community | Q36643547 | ||
| ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain | Q37379675 | ||
| Serum sphingomyelins and ceramides are early predictors of memory impairment | Q37437931 | ||
| Sphingolipids and insulin resistance: the five Ws. | Q37705954 | ||
| Amyloid beta oligomerization is induced by brain lipid rafts | Q40276012 | ||
| Astroglial expression of ceramide in Alzheimer's disease brains: a role during neuronal apoptosis. | Q40482351 | ||
| Ceramide directly activates protein kinase C zeta to regulate a stress-activated protein kinase signaling complex | Q40858625 | ||
| Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid | Q44014100 | ||
| Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer's disease: potential role in disease pathogenesis | Q44163309 | ||
| Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis | Q44370232 | ||
| Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3β, and induction of the mitochondrial-dependent intrinsic caspase pathway | Q44400926 | ||
| Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors | Q44435276 | ||
| Association of ceramides in human plasma with risk factors of atherosclerosis | Q44772533 | ||
| Mechanism of amyloid β-protein aggregation mediated by GM1 ganglioside clusters. | Q45931841 | ||
| Death or survival: membrane ceramide controls the fate and activation of antigen-specific T-cells depending on signal strength and duration. | Q46649324 | ||
| Lipids as modulators of proteolytic activity of BACE: involvement of cholesterol, glycosphingolipids, and anionic phospholipids in vitro | Q46663698 | ||
| Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin | Q46755710 | ||
| Lipid membrane templates the ordering and induces the fibrillogenesis of Alzheimer's disease amyloid-beta peptide | Q46814799 | ||
| Alzheimer peptides perturb lipid-regulating enzymes | Q46873173 | ||
| Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer's disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer's disease? | Q48251608 | ||
| Role of MAPK in ceramide-induced cell death in primary cultured astrocytes from mouse embryonic brain. | Q48787493 | ||
| Association between executive attention and physical functional performance in community-dwelling older women. | Q51980484 | ||
| Ganglioside GM1-Mediated Amyloid-beta Fibrillogenesis and Membrane Disruption† | Q57365077 | ||
| Preclinical mobility disability predicts incident mobility disability in older women | Q73554971 | ||
| Plasma sphingomyelin and subclinical atherosclerosis: findings from the multi-ethnic study of atherosclerosis | Q83149821 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| ceramides | Q424213 | ||
| P304 | page(s) | 633-641 | |
| P577 | publication date | 2012-07-18 | |
| P1433 | published in | Neurology | Q1161692 |
| P1476 | title | Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. | |
| P478 | volume | 79 |
| Q47146081 | A Lipidomics Approach to Assess the Association Between Plasma Sphingolipids and Verbal Memory Performance in Coronary Artery Disease Patients Undertaking Cardiac Rehabilitation: A C18:0 Signature for Cognitive Response to Exercise. |
| Q37692220 | APP Function and Lipids: A Bidirectional Link |
| Q33964297 | Acid sphingomyelinase modulates the autophagic process by controlling lysosomal biogenesis in Alzheimer's disease |
| Q92205921 | Advances in determining signaling mechanisms of ceramide and role in disease |
| Q92082191 | Alteration of Sphingolipids in Biofluids: Implications for Neurodegenerative Diseases |
| Q53331705 | Alzheimer disease: blood-based biomarkers in AD--a silver lining on the horizon. |
| Q92300845 | An Exploratory Phase IIa Study of the PPAR delta/gamma Agonist T3D-959 Assessing Metabolic and Cognitive Function in Subjects with Mild to Moderate Alzheimer's Disease |
| Q40444820 | Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease |
| Q91194967 | Associations of plasma very-long-chain SFA and the metabolic syndrome in adults |
| Q26740418 | Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications |
| Q34223486 | Blockade of lysosomal acid ceramidase induces GluN2B-dependent Tau phosphorylation in rat hippocampal slices. |
| Q93075146 | Body Mass Index in Multiple Sclerosis modulates ceramide-induced DNA methylation and disease course |
| Q28547451 | Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties |
| Q101476188 | Ceramide analog [18F]F-HPA-12 detects sphingolipid disbalance in the brain of Alzheimer's disease transgenic mice by functioning as a metabolic probe |
| Q38607507 | Ceramide and Its Related Neurochemical Networks as Targets for Some Brain Disorder Therapies |
| Q28087030 | Ceramides in Alzheimer's Disease: Key Mediators of Neuronal Apoptosis Induced by Oxidative Stress and Aβ Accumulation |
| Q35065194 | Ceramides predict verbal memory performance in coronary artery disease patients undertaking exercise: a prospective cohort pilot study |
| Q34422726 | Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics |
| Q34223125 | Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease |
| Q33752058 | Circulating biomarkers that predict incident dementia |
| Q92721755 | Circulating ceramide ratios and risk of vascular brain aging and dementia |
| Q50481966 | Clozapine Modulates Glucosylceramide, Clears Aggregated Proteins, and Enhances ATG8/LC3 in Caenorhabditis elegans. |
| Q93186219 | Comparison of Single Phase and Biphasic Extraction Protocols for Lipidomic Studies Using Human Plasma |
| Q38833111 | Compounds of the sphingomyelin-ceramide-glycosphingolipid pathways as secondary messenger molecules: new targets for novel therapies for fatty liver disease and insulin resistance |
| Q36768801 | Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease? |
| Q47407341 | Decreased ceramide underlies mitochondrial dysfunction in Charcot-Marie-Tooth 2F. |
| Q36409995 | Demographic and clinical variables affecting mid- to late-life trajectories of plasma ceramide and dihydroceramide species |
| Q64228448 | Developmental Comparison of Ceramide in Wild-Type and Mouse Brains and Sera |
| Q46426783 | Differential regulation of sphingolipid metabolism in plasma, hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents. |
| Q35008258 | Emerging biomarkers in cognition |
| Q58803874 | Evaluation of serum sphingolipids and the influence of genetic risk factors in age-related macular degeneration |
| Q97649423 | Genetic and environmental determinants of variation in the plasma lipidome of older Australian twins |
| Q46000358 | Genetic variation modifies risk for neurodegeneration based on biomarker status. |
| Q36436743 | HDL-cholesterol and apolipoproteins in relation to dementia |
| Q37389500 | Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab. |
| Q36166971 | Interictal, circulating sphingolipids in women with episodic migraine: A case-control study |
| Q34019193 | Is Alzheimer's disease a systemic disease? |
| Q39352421 | Lipidomic Profiles in Diabetes and Dementia. |
| Q90692297 | Low Plasma Sphingomyelin Levels Show a Weak Association with Poor Neurological Outcome in Cardiac Arrest Patients: Results from the Prospective, Observational COMMUNICATE Trial |
| Q42573873 | Markedly perturbed hematopoiesis in acid ceramidase deficient mice |
| Q39181900 | Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid. |
| Q33627250 | Multivariate analysis reveals genetic associations of the resting default mode network in psychotic bipolar disorder and schizophrenia |
| Q47099182 | Neuroprotection through flavonoid: Enhancement of the glyoxalase pathway |
| Q30363059 | Neutral Sphingomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse |
| Q39320214 | Omega-3 fatty acids, lipids and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention. |
| Q36973077 | Peripheral sphingolipids are associated with variation in white matter microstructure in older adults |
| Q46563505 | Plasma Ceramides and Neuropsychiatric Symptoms of Alzheimer's Disease |
| Q37091714 | Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study |
| Q34994293 | Plasma ceramide and glucosylceramide metabolism is altered in sporadic Parkinson's disease and associated with cognitive impairment: a pilot study |
| Q36855949 | Plasma sphingolipid changes with autopsy-confirmed Lewy Body or Alzheimer's pathology |
| Q90589264 | Potential therapeutic target for aging and age-related neurodegenerative diseases: the role of acid sphingomyelinase |
| Q38125769 | Progress towards a consensus on biomarkers for Alzheimer's disease: a review of peripheral analytes. |
| Q26828606 | Recent advances in the application of metabolomics to Alzheimer's Disease |
| Q38262594 | Resveratrol and its oligomers: modulation of sphingolipid metabolism and signaling in disease |
| Q57177438 | Role of sphingolipids in senescence: implication in aging and age-related diseases |
| Q37109693 | Serum sphingolipidomic analyses reveal an upregulation of C16-ceramide and sphingosine-1-phosphate in hepatocellular carcinoma |
| Q90089057 | Sets of coregulated serum lipids are associated with Alzheimer's disease pathophysiology |
| Q89983254 | Sex and APOE ε4 genotype modify the Alzheimer's disease serum metabolome |
| Q46753548 | Skeletal muscle ceramide species in men with abdominal obesity |
| Q37586487 | Sphingolipids and lifespan regulation |
| Q90010373 | Sphingolipids as Biomarkers of Disease |
| Q57070720 | Sphingolipids in neurodegeneration (with focus on ceramide and S1P) |
| Q47619472 | Synthesis, Radiosynthesis, and Preliminary in vitro and in vivo Evaluation of the Fluorinated Ceramide Trafficking Inhibitor (HPA-12) for Brain Applications |
| Q36121819 | The 5XFAD Mouse Model of Alzheimer's Disease Exhibits an Age-Dependent Increase in Anti-Ceramide IgG and Exogenous Administration of Ceramide Further Increases Anti-Ceramide Titers and Amyloid Plaque Burden |
| Q40401973 | The Association Between Plasma Ceramides and Sphingomyelins and Risk of Alzheimer's Disease Differs by Sex and APOE in the Baltimore Longitudinal Study of Aging. |
| Q36209750 | The Effects of Long-Term Saturated Fat Enriched Diets on the Brain Lipidome. |
| Q43988916 | The impact of cholesterol, DHA, and sphingolipids on Alzheimer's disease |
| Q49917617 | The serum metabolomics signature of Type 2 Diabetes is obscured in Alzheimer's Disease |
| Q41687237 | Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection |
| Q61797514 | Very Long-Chain C24:1 Ceramide Is Increased in Serum Extracellular Vesicles with Aging and Can Induce Senescence in Bone-Derived Mesenchymal Stem Cells |
Search more.